Skip to content

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

Verizon mHealth Solution for Elderly Underserved Patients With Peripheral Artery Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02472561
Enrollment
22
Registered
2015-06-16
Start date
2015-07-31
Completion date
2017-11-07
Last updated
2018-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Artery Disease

Keywords

Cardiology, Vascular, Peripheral Artery Disease, Artery, Mobile Health, Exercise, PAD

Brief summary

The purpose of this study is to understand the effects that a three month lifestyle-based mobile health (mHealth) peripheral artery disease (PAD) prevention program will have on improving physical activity, fitness, important PAD risk factors and quality of life (QOL) in patients with PAD. By testing a novel mHealth intervention focused on lifestyle modification, this trial will address a critical evidence gap in the care of PAD patients. PAD patients are not eligible for cardiac rehabilitation and therefore struggle with unhealthy lifestyles, and these patients currently have no lifestyle-based care strategies to help them. The results of this study have the potential to lead to new sustainable and resource-efficient, lifestyle-based preventive care strategies for patients with stable PAD.

Detailed description

This is a single-center, randomized trial designed to examine the hypothesis that a lifestyle-based mHealth peripheral artery disease (PAD) prevention program will improve physical activity, fitness, important PAD risk factors and quality of life (QOL). The investigators may enroll up to 55 men and women being evaluated for leg pain from Duke PAD cardiovascular clinics or after lower extremity angioplasty in the Duke catheterization laboratory. Of the 55 men and women volunteers who may be initially consented, the investigators anticipate a portion (potentially 20%) may drop out during the study timeline, and approximately 45 are expected to complete this study. Following informed consent and baseline testing, the participants will be randomized (1.25:1.00) into either a mHealth (N=25) or usual care group (N=20) \[for comparison\] for a 12-week period. All patients will be evaluated for walking ability on a treadmill test, quality of life questionnaires, health literacy related to PAD and the most important risk factors specific to PAD (blood glucose if diabetic, daily physical activity and blood pressure).

Interventions

OTHERFitbit Physical Activity Monitor

Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.

OTHERmHealth Glucometer

Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.

OTHERmHealth Blood Pressure

Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.

Sponsors

Verizon Wireless
CollaboratorINDUSTRY
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention * A history of stable intermittent claudication for \>2 months, and an ABI \<0.9 at rest * No contraindications to exercise training * All subjects will be on the recommended regimen of statin and antiplatelet therapy * Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study

Exclusion criteria

* Present or a past history of gangrene, impending limb loss or osteomyelitis * Severe peripheral neuropathy * Any condition other than PAD that limits walking for example arthritis or chronic obstructive pulmonary disease (COPD) * Unstable angina, history of significant left main disease or three vessel coronary artery disease (\>70% stenosis, unprotected by grafts) or recent myocardial infarction (less than eight weeks) * Chest pain during treadmill exercise which appears before the onset of claudication, or 2 mm ST depression during exercise regardless of the results of tests for myocardial ischemia * Refusal or inability to give informed consent or inability or unwillingness to comply with the study requirements. * Dementia that precludes ability to participate in and follow study protocols * Enrollment in a clinical trial not approved for co-enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Change in cardiovascular fitness level measured by change score analysis of peak Volume of Oxygen (pVO2mL/kg/min) consumption measured during a cardiopulmonary exercise test (CPET).Baseline and 12-weekpeak VO2 mL/kg/min

Secondary

MeasureTime frameDescription
Feasibility of this novel mobile health treatment strategy, as measured by patient satisfaction survey12-weekPatient Satisfaction Survey
Implementation of this novel mobile health treatment strategy, as measured by patient satisfaction12-weekPatient Satisfaction Survey
Change in physical activity patterns (steps, time and distance)Baseline and 12-weekSteps, time and distance per week
Change score analysis in Blood Glucose measurementsBaseline and 12-weekFasting Plasma Glucose and Hemoglobin A1-C
Change score analysis in Body Mass Index measurementsBaseline and 12-weekRatio of height to weight
Change in Quality of Life (QOL) scores on the Walking Impairment QuestionnaireBaseline and 12-week
Change in Peripheral Artery Disease (PAD) Health Aptitude scores on the Health Aptitude QuestionnaireBaseline and 12-week
Change in Smoking Habits scores on the PAD: Smoking Habit QuestionnaireBaseline and 12-week
Change score analysis in Systolic and Diastolic Blood Pressure measurementsBaseline and 12-week
Change in Medication Adherence scores as measured by the Morisky Medication Adherence Scale (MMAS-8)Baseline and 12-week

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026